These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11474280)

  • 1. Is MUGA scan necessary in patients with low-risk breast cancer before doxorubicin-based adjuvant therapy? Multiple gated acquisition.
    Sabel MS; Levine EG; Hurd T; Schwartz GN; Zielinski R; Hohn D; Edge SB
    Am J Clin Oncol; 2001 Aug; 24(4):425-8. PubMed ID: 11474280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Routine cardiac evaluation in patients with early-stage breast cancer before adjuvant chemotherapy.
    Jeyakumar A; DiPenta J; Snow S; Rayson D; Thompson K; Theriault C; Younis T
    Clin Breast Cancer; 2012 Feb; 12(1):4-9. PubMed ID: 22154116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients.
    Cho H; Lee S; Sim SH; Park IH; Lee KS; Kwak MH; Kim HJ
    Breast Cancer Res Treat; 2020 Jul; 182(2):333-343. PubMed ID: 32468335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer.
    Klein JL; Rey PM; Dansey RD; Karanes C; Du W; Abella E; Cassells L; Hamm C; Peters WP; Baynes RD
    Bone Marrow Transplant; 2000 May; 25(10):1047-52. PubMed ID: 10828864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies.
    Uyar D; Kulp B; Peterson G; Zanotti K; Markman M; Belinson J
    Gynecol Oncol; 2004 Jul; 94(1):147-51. PubMed ID: 15262133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation.
    Zambetti M; Moliterni A; Materazzo C; Stefanelli M; Cipriani S; Valagussa P; Bonadonna G; Gianni L
    J Clin Oncol; 2001 Jan; 19(1):37-43. PubMed ID: 11134193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High incidence of adriamycin cardiotoxicity in children even at low cumulative doses: role of radionuclide cardiac angiography.
    Agarwala S; Kumar R; Bhatnagar V; Bajpai M; Gupta DK; Mitra DK
    J Pediatr Surg; 2000 Dec; 35(12):1786-9. PubMed ID: 11101737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and economic impact of multiple gated acquisition scan monitoring during anthracycline therapy.
    Shureiqi I; Cantor SB; Lippman SM; Brenner DE; Chernew ME; Fendrick AM
    Br J Cancer; 2002 Jan; 86(2):226-32. PubMed ID: 11870511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer.
    Valagussa P; Zambetti M; Biasi S; Moliterni A; Zucali R; Bonadonna G
    Ann Oncol; 1994 Mar; 5(3):209-16. PubMed ID: 8186169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
    Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dexrazoxane added to doxorubicin-based adjuvant chemotherapy of breast cancer: a retrospective cohort study with a comparative analysis of toxicity and survival.
    Tahover E; Segal A; Isacson R; Rosengarten O; Grenader T; Gips M; Cherny N; Heching NI; Mesika L; Catane R; Gabizon A
    Anticancer Drugs; 2017 Aug; 28(7):787-794. PubMed ID: 28562379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adjuvant anthracycline therapy.
    Lluch A; Ojeda B; Colomer R; Barnadas A; Massuti B; Casado A; Angeles C; Maroto P
    Cancer; 2000 Dec; 89(11):2169-75. PubMed ID: 11147586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The utility of routine pre-chemotherapy screening with cardiac gated blood pool scan for patients at low risk of anthracycline toxicity.
    Chia PL; Chiang K; Snyder R; Dowling A
    J Oncol Pharm Pract; 2018 Jun; 24(4):264-271. PubMed ID: 29284360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.
    Speyer JL; Green MD; Zeleniuch-Jacquotte A; Wernz JC; Rey M; Sanger J; Kramer E; Ferrans V; Hochster H; Meyers M
    J Clin Oncol; 1992 Jan; 10(1):117-27. PubMed ID: 1727913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuing routine cardiac surveillance in long-term use of pegylated liposomal doxorubicin: is it necessary?
    Gill SE; Savage K; Wysham WZ; Blackhurst DW; Winter WE; Puls LE
    Gynecol Oncol; 2013 Jun; 129(3):544-7. PubMed ID: 23523653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast.
    Speyer JL; Green MD; Dubin N; Blum RH; Wernz JC; Roses D; Sanger J; Muggia FM
    Am J Med; 1985 Apr; 78(4):555-63. PubMed ID: 3838618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience.
    Diamandidou E; Buzdar AU; Smith TL; Frye D; Witjaksono M; Hortobagyi GN
    J Clin Oncol; 1996 Oct; 14(10):2722-30. PubMed ID: 8874333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer.
    Abu-Khalaf MM; Juneja V; Chung GG; DiGiovanna MP; Sipples R; McGurk M; Zelterman D; Haffty B; Reiss M; Wackers FJ; Lee FA; Burtness BA
    Breast Cancer Res Treat; 2007 Sep; 104(3):341-9. PubMed ID: 17051423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy.
    Blaes AH; Gaillard P; Peterson BA; Yee D; Virnig B
    Breast Cancer Res Treat; 2010 Jul; 122(2):585-90. PubMed ID: 20058065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients.
    Shapiro CL; Hardenbergh PH; Gelman R; Blanks D; Hauptman P; Recht A; Hayes DF; Harris J; Henderson IC
    J Clin Oncol; 1998 Nov; 16(11):3493-501. PubMed ID: 9817266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.